Article
Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
PloS one - 1 Jan 2021
Umamaheswaran Gurusamy, Kadambari Dharanipragada, Muthuvel Suresh Kumar, Kumar Naveena A N, Dubashi Biswajit, Aibor Dkhar Steven, Adithan Chandrasekaran
Abstract excerpt
Letrozole, an aromatase inhibitor (AI), is the first-line adjuvant drug for treating hormone receptor-positive (HR+) breast cancer in postmenopausal women. However, harmful adverse events (AEs) and significant differences in drug response among individuals remain a significant problem in clinical application. Current evidence suggests that the observed individual variation in the treatment outcomes of AI is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.